Sophie Dreux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sophie Dreux has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Etienne Voirin‐Mathieu
Biochimie‐Hormonologie Hôpital R. Debré DMU Biogem AP‐HP Paris France
2 shared publicationsEve Mousty
Centre Hospitalier Universitaire de Nîmes Gynecology and Obstetrics Nimes Nimes France
2 shared publicationsFrançoise Muller
Biochimie‐Hormonologie Hôpital R. Debré DMU Biogem AP‐HP Paris France
2 shared publications- Jonathan Rosenblatt
Unité de Médecine Foetale, DMU Gynécologie Périnatalité, APHP, Hôpital Robert Debré, Paris, France
2 shared publications - Yves Ville
Department of Obstetrics, Fetal Medicine and Surgery, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Ville); URP 7328 FETUS, Université Paris Cité, Paris, France (Ville)
2 shared publications A. Andreev
Université Paris VI
1 shared publication
Latest Publications
- Open Access
- 17 May 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (8) , 959-964
Very elevated hCGβ (≥10 multiple of the median) in maternal marker screening for Down syndrome: Frequency, etiologies, outcomes, and guidelines
AimThis aim of this study was to detail maternal and fetal anomalies observed on a national scale in a large French cohort of patients presenting high hCG values (>= 10 multiple of the median [MoM]) at Down syndrome screening in order to define clear and optimal guidelines.MethodsThis is a retrospective multicenter study based on a French annual database of all trisomy 21 screenings. Our study targeted and studied cases with hCG or hCG beta values >= 10 MoM. Complementary exams and outcomes were analyzed.ResultsThe calculated frequency was 0.05% for hCG beta >= 10 MoM in unselected patients. For this series of 289 cases, a complication of the pregnancy or a poor outcome was observed in 145 cases (51%) as follows: 96 (66%) cases of fetal disease, 23 (16%) of maternal disease, 5 (3.5%) of placental anomalies and 21 (14.5%) of systemic disease concerning mother, fetus and placenta.ConclusionThis study establishes the frequency of hCG or hCG beta values >= 10 MoM, presents a flow chart that optimizes follow-up, and gives clear information for patients presenting with such abnormal values at trisomy 21 screening. What's already known about this topic?High hCG or hCG beta values have been previously reported to be associated with poor prognosis, when over 2.5 multiple of the median (MoM).What does this study add?This study specifies maternal and fetal anomalies observed in patients presenting high hCG values (>= 10 MoM) at Down syndrome screening in order to define clear and optimal guidelines. We calculate the frequency of this abnormal value of hCG beta, detail the outcomes, present a flow chart that optimizes follow-up and provide clear information for patients.
- 17 May 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (8) , 959-964
Open AccessVery elevated hCGβ (≥10 multiple of the median) in maternal marker screening for Down syndrome: Frequency, etiologies, outcomes, and guidelines
AimThis aim of this study was to detail maternal and fetal anomalies observed on a national scale in a large French cohort of patients presenting high hCG values (>= 10 multiple of the median [MoM]) at Down syndrome screening in order to define clear and optimal guidelines.MethodsThis is a retrospective multicenter study based on a French annual database of all trisomy 21 screenings. Our study targeted and studied cases with hCG or hCG beta values >= 10 MoM. Complementary exams and outcomes were analyzed.ResultsThe calculated frequency was 0.05% for hCG beta >= 10 MoM in unselected patients. For this series of 289 cases, a complication of the pregnancy or a poor outcome was observed in 145 cases (51%) as follows: 96 (66%) cases of fetal disease, 23 (16%) of maternal disease, 5 (3.5%) of placental anomalies and 21 (14.5%) of systemic disease concerning mother, fetus and placenta.ConclusionThis study establishes the frequency of hCG or hCG beta values >= 10 MoM, presents a flow chart that optimizes follow-up, and gives clear information for patients presenting with such abnormal values at trisomy 21 screening. What's already known about this topic?High hCG or hCG beta values have been previously reported to be associated with poor prognosis, when over 2.5 multiple of the median (MoM).What does this study add?This study specifies maternal and fetal anomalies observed in patients presenting high hCG values (>= 10 MoM) at Down syndrome screening in order to define clear and optimal guidelines. We calculate the frequency of this abnormal value of hCG beta, detail the outcomes, present a flow chart that optimizes follow-up and provide clear information for patients.
- Open Access
- 13 February 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (2) , e2397
Antenatal description of large 4q13.2q21.23 deletion and outcomes
Background: 4q21 microdeletion syndrome is an emergent non‐recurrent genomic disorder characterized by facial dysmorphy, progressive growth retardation, severe intellectual deficit, and absent or severely delayed speech. Deletions occur in clusters along 4q interstitial or terminal regions. 4q chromosomal aberrations are variable in type, size, and breakpoint. Genotype–phenotype correlation is a challenging task. The recurrent antenatal feature associated a posteriori with this syndrome is intrauterine growth retardation. There are very few precise antenatal descriptions of this syndrome.Methods: We report here the first antenatal history of one of the largest deletion of this region.Results: Our case harbored a 16.9 Mb deletion encompassing 135 protein coding genes including 20 OMIM morbid genes involved in neurological and cognitive abilities. Those breakpoints overlap two clusters of described microdeletion syndromes of cytogenetic band 4q13 and 4q21.Conclusion: From the end of the second trimester, set of call signs associated with this syndrome can be completed by: excess of amniotic fluid, mild growth retardation, short long bones, bony anomalies of the extremities, and bulging cheeks. So, emphasis should be placed on the examination of the extremities, and the face during the routine targeted prenatal ultrasound.
- 13 February 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (2) , e2397
Open AccessAntenatal description of large 4q13.2q21.23 deletion and outcomes
Background: 4q21 microdeletion syndrome is an emergent non‐recurrent genomic disorder characterized by facial dysmorphy, progressive growth retardation, severe intellectual deficit, and absent or severely delayed speech. Deletions occur in clusters along 4q interstitial or terminal regions. 4q chromosomal aberrations are variable in type, size, and breakpoint. Genotype–phenotype correlation is a challenging task. The recurrent antenatal feature associated a posteriori with this syndrome is intrauterine growth retardation. There are very few precise antenatal descriptions of this syndrome.Methods: We report here the first antenatal history of one of the largest deletion of this region.Results: Our case harbored a 16.9 Mb deletion encompassing 135 protein coding genes including 20 OMIM morbid genes involved in neurological and cognitive abilities. Those breakpoints overlap two clusters of described microdeletion syndromes of cytogenetic band 4q13 and 4q21.Conclusion: From the end of the second trimester, set of call signs associated with this syndrome can be completed by: excess of amniotic fluid, mild growth retardation, short long bones, bony anomalies of the extremities, and bulging cheeks. So, emphasis should be placed on the examination of the extremities, and the face during the routine targeted prenatal ultrasound.
- Open Access
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (1) , 28-34
Postnatal outcome of children with antenatal colonic hyperechogenicity
Objective: To evaluate the postnatal outcome of children with antenatal colonic hyperechogenicity, currently considered as a sign of lysinuria‐cystinuria, but which may also be a sign of other disorders with a more severe prognosis.Method: We carried out a French multi‐centric retrospective study via 15 Multidisciplinary Center for Prenatal Diagnosis from January 2011 to January 2021. We included pregnancies for which fetal colonic hyperechogenicity had been demonstrated. We collected the investigations performed during pregnancy and at birth as well as the main clinical features of the mother and the child. We then established the prevalence of pathologies such as lysinuria‐cystinuria (LC), hypotonia‐cystinuria syndrome (HC), or lysinuric protein intolerance (LPI).Results: Among the 33 cases of colonic hyperechogenicity collected, and after exclusion of those lost to follow‐up, we identified 63% of children with lysinuria‐cystinuria, 8% with lysinuric rotein intolerance, and 4% with hypotonia‐cystinuria syndrome.Conclusion: Management of prenatal hyperechoic colon should include a specialized consultation with a clinical geneticist to discuss further investigations, which could include invasive amniotic fluid sampling for molecular diagnosis. A better understanding of diagnoses and prognosis should improve medical counseling and guide parental decision making.
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (1) , 28-34
Open AccessPostnatal outcome of children with antenatal colonic hyperechogenicity
Objective: To evaluate the postnatal outcome of children with antenatal colonic hyperechogenicity, currently considered as a sign of lysinuria‐cystinuria, but which may also be a sign of other disorders with a more severe prognosis.Method: We carried out a French multi‐centric retrospective study via 15 Multidisciplinary Center for Prenatal Diagnosis from January 2011 to January 2021. We included pregnancies for which fetal colonic hyperechogenicity had been demonstrated. We collected the investigations performed during pregnancy and at birth as well as the main clinical features of the mother and the child. We then established the prevalence of pathologies such as lysinuria‐cystinuria (LC), hypotonia‐cystinuria syndrome (HC), or lysinuric protein intolerance (LPI).Results: Among the 33 cases of colonic hyperechogenicity collected, and after exclusion of those lost to follow‐up, we identified 63% of children with lysinuria‐cystinuria, 8% with lysinuric rotein intolerance, and 4% with hypotonia‐cystinuria syndrome.Conclusion: Management of prenatal hyperechoic colon should include a specialized consultation with a clinical geneticist to discuss further investigations, which could include invasive amniotic fluid sampling for molecular diagnosis. A better understanding of diagnoses and prognosis should improve medical counseling and guide parental decision making.
- Open Access
- 17 January 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (3) , 328-338
Fetal intestinal loop dilatation: Follow‐up and outcome of a series of 133 consecutive cases (the DILDIG study)
Objectives: To define the prognostic markers of fetal dilated bowel loops.Methods: National non‐interventional study of 133 consecutive prenatal observations of dilated loops including ultrasound examinations, complementary laboratory tests, magnetic resonance imaging (MRI), outcomes, and postnatal diagnosis.Results: One hundred twenty seven cases were classified according to outcome: Group 1, very severe (n = 43), Group 2, children needing specific care (n = 39), and Group 3, healthy children (n = 45). Prenatal ultrasound scan suggested duodenal obstruction in 30 cases, small bowel obstruction in 81, colonic obstruction in 11, and diffuse dilatation in 5. Diameter of dilated loops did not significantly differ between the groups. A poor prognosis was significantly associated with duodenal obstruction, genetic anomalies (53% vs. 21.8%), including aneuploidies or CFTR gene mutations and abnormal amniotic fluid biochemistry (86.4% vs. 38.7%). A good prognosis was associated with regression of dilatation and normal MRI.Conclusion: In this study, postnatal outcomes for fetuses with intestinal dilatation were best predicted by assessing the level of obstruction with prenatal ultrasound and MRI, determining the presence of associated malformations, amniotic fluid biochemical and genetic testing, and monitoring for regression of bowel dilatation. These results should help inform future guidelines on the prenatal and neonatal management of congenital intestinal obstruction.
- 17 January 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (3) , 328-338
Open AccessFetal intestinal loop dilatation: Follow‐up and outcome of a series of 133 consecutive cases (the DILDIG study)
Objectives: To define the prognostic markers of fetal dilated bowel loops.Methods: National non‐interventional study of 133 consecutive prenatal observations of dilated loops including ultrasound examinations, complementary laboratory tests, magnetic resonance imaging (MRI), outcomes, and postnatal diagnosis.Results: One hundred twenty seven cases were classified according to outcome: Group 1, very severe (n = 43), Group 2, children needing specific care (n = 39), and Group 3, healthy children (n = 45). Prenatal ultrasound scan suggested duodenal obstruction in 30 cases, small bowel obstruction in 81, colonic obstruction in 11, and diffuse dilatation in 5. Diameter of dilated loops did not significantly differ between the groups. A poor prognosis was significantly associated with duodenal obstruction, genetic anomalies (53% vs. 21.8%), including aneuploidies or CFTR gene mutations and abnormal amniotic fluid biochemistry (86.4% vs. 38.7%). A good prognosis was associated with regression of dilatation and normal MRI.Conclusion: In this study, postnatal outcomes for fetuses with intestinal dilatation were best predicted by assessing the level of obstruction with prenatal ultrasound and MRI, determining the presence of associated malformations, amniotic fluid biochemical and genetic testing, and monitoring for regression of bowel dilatation. These results should help inform future guidelines on the prenatal and neonatal management of congenital intestinal obstruction.
- 28 June 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (4) , 513-521
Pathological and sonographic review of early isolated severe lower urinary tract obstruction and implications for prenatal treatment
Objectives Rationale for prenatal therapy in lower urinary tract obstruction (LUTO) is debated. The aim of this study was to identify favorable renal histology in early severe LUTO and determine timing and selection criteria for prenatal surgery. Methods This multicentric retrospective study included male fetuses with severe LUTO deceased before 24 weeks of gestation (January 2000-December 2018). Age-paired controls were used as standard for renal histology. Prenatal ultrasound features, fetal serum and/or urine β2microglobulin and kidney slides (Hematein-Eosin-Safran, α-smooth-muscle actin (αSMA) immunostaining) were reviewed. αSMA positive staining of the blastema relates to its aberrant differentiation into myofibroblastic cells. Cases were sorted into histopathologic groups (favorable or unfavorable) according to blastema's morphology and αSMA labelling. Results Seventy-four fetuses were included at a median gestational age of 17.6 weeks’ [13-23.5]. Parenchymal organization was preserved in 48% of the kidneys. Although blastema was present in 90% of them, it was morphologically normal in only 9% and αSMA negative in only 1% of them. Most fetuses had an unfavorable prognosis (82%), including early renal lesions (≤ 18 weeks’) in 36% of them. Fetuses with an early gestational age were associated with a favorable renal prognosis (p=0.001). LUTO fetuses had a significant reduction in mature glomeruli (p<0.001) compared to controls. However, no significant reduction in glomeruli generations was found between the early unfavorable prognosis group (≤ 18 weeks’) and the favorable one (p=0.19). Comparison of prenatal ultrasound features and biochemical markers between groups could not identify any prenatal selection criteria. Conclusions Before 18 weeks’, around 30% of fetuses with severe LUTO still have potential for kidney development. Prenatal therapeutic strategy could therefore have a better impact if they could identify these cases.
- 28 June 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (4) , 513-521
Pathological and sonographic review of early isolated severe lower urinary tract obstruction and implications for prenatal treatment
Objectives Rationale for prenatal therapy in lower urinary tract obstruction (LUTO) is debated. The aim of this study was to identify favorable renal histology in early severe LUTO and determine timing and selection criteria for prenatal surgery. Methods This multicentric retrospective study included male fetuses with severe LUTO deceased before 24 weeks of gestation (January 2000-December 2018). Age-paired controls were used as standard for renal histology. Prenatal ultrasound features, fetal serum and/or urine β2microglobulin and kidney slides (Hematein-Eosin-Safran, α-smooth-muscle actin (αSMA) immunostaining) were reviewed. αSMA positive staining of the blastema relates to its aberrant differentiation into myofibroblastic cells. Cases were sorted into histopathologic groups (favorable or unfavorable) according to blastema's morphology and αSMA labelling. Results Seventy-four fetuses were included at a median gestational age of 17.6 weeks’ [13-23.5]. Parenchymal organization was preserved in 48% of the kidneys. Although blastema was present in 90% of them, it was morphologically normal in only 9% and αSMA negative in only 1% of them. Most fetuses had an unfavorable prognosis (82%), including early renal lesions (≤ 18 weeks’) in 36% of them. Fetuses with an early gestational age were associated with a favorable renal prognosis (p=0.001). LUTO fetuses had a significant reduction in mature glomeruli (p<0.001) compared to controls. However, no significant reduction in glomeruli generations was found between the early unfavorable prognosis group (≤ 18 weeks’) and the favorable one (p=0.19). Comparison of prenatal ultrasound features and biochemical markers between groups could not identify any prenatal selection criteria. Conclusions Before 18 weeks’, around 30% of fetuses with severe LUTO still have potential for kidney development. Prenatal therapeutic strategy could therefore have a better impact if they could identify these cases.
- 22 December 2020
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (4) , 434-439
Prenatal biochemical diagnosis of two forms of congenital diarrheal disorders (congenital chloride diarrhea and congenital sodium diarrhea): A series of 12 cases
Objective: Congenital diarrheal disorders (CDDs) are a group of rare diseases among which some present as inherited disorders of intestinal electrolyte transportation: congenital chloride diarrhea (CCD) and congenital sodium diarrhea (CSD) with prenatal manifestations, mainly polyhydramnios, leading to premature delivery. Affected neonates present with watery stools, sometimes mistaken as urine, leading to a misdiagnosis of Bartter syndrome. The aim of this study was to study the value of a prenatal biochemical pattern in the case of suspected CDD.Methods: We retrospectively studied 12 amniotic fluids of CDD‐affected fetuses prenatally suspected and confirmed after birth. Digestive enzymes, proteins, and electrolytes were assayed and showed abnormal biochemical patterns.Results: The 12 infants (eight CCD‐ and four CSD‐affected) were born prematurely with a normal birth weight. Electrolytes and the Bartter index were normal for all cases. Amniotic fluid enzyme patterns were abnormal: anal leakage for nine, as expected, but vomiting of bile was observed for three infants, for whom an occlusive syndrome required surgery, and thereafter severe complications appeared with a poor prognosis.Conclusion: Amniotic fluid biochemical patterns differentiate CDD from Bartter syndrome. If a vomiting bile pattern is observed, postnatal management should take into account the hypothesis of a most severe complication.
- 22 December 2020
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (4) , 434-439
Prenatal biochemical diagnosis of two forms of congenital diarrheal disorders (congenital chloride diarrhea and congenital sodium diarrhea): A series of 12 cases
Objective: Congenital diarrheal disorders (CDDs) are a group of rare diseases among which some present as inherited disorders of intestinal electrolyte transportation: congenital chloride diarrhea (CCD) and congenital sodium diarrhea (CSD) with prenatal manifestations, mainly polyhydramnios, leading to premature delivery. Affected neonates present with watery stools, sometimes mistaken as urine, leading to a misdiagnosis of Bartter syndrome. The aim of this study was to study the value of a prenatal biochemical pattern in the case of suspected CDD.Methods: We retrospectively studied 12 amniotic fluids of CDD‐affected fetuses prenatally suspected and confirmed after birth. Digestive enzymes, proteins, and electrolytes were assayed and showed abnormal biochemical patterns.Results: The 12 infants (eight CCD‐ and four CSD‐affected) were born prematurely with a normal birth weight. Electrolytes and the Bartter index were normal for all cases. Amniotic fluid enzyme patterns were abnormal: anal leakage for nine, as expected, but vomiting of bile was observed for three infants, for whom an occlusive syndrome required surgery, and thereafter severe complications appeared with a poor prognosis.Conclusion: Amniotic fluid biochemical patterns differentiate CDD from Bartter syndrome. If a vomiting bile pattern is observed, postnatal management should take into account the hypothesis of a most severe complication.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- Open Access
- 1 February 1992
- Published by Springer Nature in Intensive Care Medicine
- Vol. 18 (2) , 69-75
Continuous positive airway pressure (CPAP) vs. intermittent mandatory pressure release ventilation (IMPRV) in patients with acute respiratory failure
Intermittent Mandatory Pressure Release Ventilation (IMPRV) is a positive pressure spontaneous breathing ventilatory mode in which airway pressure is released intermittently and synchronously with patient's spontaneous expiration in order to provide ventilatory assistance. Eight critically ill patients free of any factor known to alter chest wall mechanics (group 1) and 8 critically ill patients whose spontaneous respiratory activity was markedly altered by a flail chest, or by a C5 quadraplegia and/or by the administration of opioids (group 2) were studied prospectively. CPAP and IMPRV were administered to each patient in a random order during a 1 h period using a CESAR ventilator. Gas flow, tidal volume, tracheal pressure, esophageal pressure, end-expiratory lung volume and hemodynamic parameters were measured. In group 1 patients, the ventilatory assistance provided by IMPRV was associated with a significant decrease in spontaneous tidal volume whereas all other respiratory parameters remained unchanged. In group 2 patients, IMPRV increased minute ventilation from 8.0±2.61/min to 12.2±1.81/min (p2 from 46±7.3 mmHg to 38±6.8 mmHg (pp<0.07). These results show that IMPRV provides significant ventilatory assistance to patients with mild acute respiratory failure either by decreasing patient's contribution to minute ventilation or by increasing alveolar ventilation in presence of respiratory depression of central or peripheral origin.
- 1 February 1992
- Published by Springer Nature in Intensive Care Medicine
- Vol. 18 (2) , 69-75
Open AccessContinuous positive airway pressure (CPAP) vs. intermittent mandatory pressure release ventilation (IMPRV) in patients with acute respiratory failure
Intermittent Mandatory Pressure Release Ventilation (IMPRV) is a positive pressure spontaneous breathing ventilatory mode in which airway pressure is released intermittently and synchronously with patient's spontaneous expiration in order to provide ventilatory assistance. Eight critically ill patients free of any factor known to alter chest wall mechanics (group 1) and 8 critically ill patients whose spontaneous respiratory activity was markedly altered by a flail chest, or by a C5 quadraplegia and/or by the administration of opioids (group 2) were studied prospectively. CPAP and IMPRV were administered to each patient in a random order during a 1 h period using a CESAR ventilator. Gas flow, tidal volume, tracheal pressure, esophageal pressure, end-expiratory lung volume and hemodynamic parameters were measured. In group 1 patients, the ventilatory assistance provided by IMPRV was associated with a significant decrease in spontaneous tidal volume whereas all other respiratory parameters remained unchanged. In group 2 patients, IMPRV increased minute ventilation from 8.0±2.61/min to 12.2±1.81/min (p2 from 46±7.3 mmHg to 38±6.8 mmHg (pp<0.07). These results show that IMPRV provides significant ventilatory assistance to patients with mild acute respiratory failure either by decreasing patient's contribution to minute ventilation or by increasing alveolar ventilation in presence of respiratory depression of central or peripheral origin.